News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
292 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17903)
Month
January (4345)
February (4356)
March (4476)
April (4722)
May (4999)
June (4103)
July (3643)
August (3330)
September (4039)
October (5056)
November (4470)
December (3799)
Day
1 (18)
2 (269)
3 (285)
4 (247)
5 (261)
6 (107)
7 (40)
8 (30)
9 (292)
10 (264)
11 (234)
12 (208)
13 (114)
14 (2)
15 (9)
16 (225)
17 (227)
18 (243)
19 (266)
20 (124)
21 (3)
22 (2)
23 (119)
24 (14)
25 (1)
26 (39)
27 (24)
28 (1)
29 (2)
30 (88)
31 (41)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Drug Development
Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma
Interim Phase 2a Data Demonstrate Improved Overall Response Rate in Combination with Rituximab
December 9, 2019
·
6 min read
Genetown
Making Cell and Gene Therapies Financially Accessible and Sustainable
The Financing and Reimbursement of Cures in the US Consortium (FoCUS) launched the Paying for Cures Toolkit today.
December 9, 2019
·
4 min read
Biotech Beach
Breakthrough Findings in Leukemias Presented at ASH 2019 Demonstrate Bionano Saphyr’s Potential to Replace All Cytogenetic Methods and Show Additional Clinical Utility
Bionano’s new DNA Isolation Kit for Bone Marrow Aspirates enables routine clinical analysis of Leukemia samples.
December 9, 2019
·
6 min read
Pharm Country
Immunomedics Announces Closing of Public Offering of Common Stock
The total net proceeds from the offering for Immunomedics are estimated to be approximately $272 million, after deducting underwriting discounts and commissions but before deducting other estimated offering expenses payable by the Company.
December 9, 2019
·
3 min read
Biotech Bay
Kezar Life Sciences Highlights Therapeutic Potential of Protein Secretion Inhibitors at the 61st American Society of Hematology Annual Meeting
Two oral presentations and one poster presentation focus on novel inhibitors of the Sec61 translocon, which demonstrate high degrees of potency against a large number of therapeutically relevant oncology and immuno-oncology targets that are Sec61 client proteins, translating into broad anti-tumor activity.
December 9, 2019
·
6 min read
Business
ContraFect Corporation Announces Proposed Public Offering of Common Stock and Concurrent Private Placement of Common Stock to Pfizer Inc.
The public offering is subject to market conditions and the private placement is contingent upon the closing of the public offering, and there can be no assurance as to whether or when the public offering and private placement may be completed, or the actual size or terms of the public offering and private placement.
December 9, 2019
·
7 min read
Pharm Country
SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants
The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
December 9, 2019
·
3 min read
Beyond Cholesterol: Landmark deCODE Study Elucidates Role of Lipoprotein(a) as Major Risk Factor for Heart Disease
Highly diverse, understudied and not routinely screened for, Lp(a) -- an alipoprotein(a) bound to an LDL cholesterol particle -- may be the next most important serum risk factor after LDL itself
December 9, 2019
·
4 min read
Drug Development
Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias
Data provide detailed look at potential underlying mechanism of action within cells
December 9, 2019
·
6 min read
Drug Development
Supernus Provides Update on Results from Phase III Study (P301) of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients
In early November 2019, the Company reported topline results from the Phase III P301 trial in patients 6 to 11 years.
December 9, 2019
·
6 min read
Previous
20 of 30
Next